Skip to Main Content
DownloadHi-Res Photo

Benjamin L. Judson, MD

Professor of Surgery (Otolaryngology); Chief, Division of Otolaryngology, Yale Medicine

Contact Information

Benjamin L. Judson, MD

Mailing Address

  • Otolaryngology Surgery

    330 Cedar Street, PO Box 208041

    New Haven, CT, 06520-8041

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

My research interests include investigating outcomes and quality in head and neck cancer therapy, participating in clinical trials, and leading a bio-repository of head and neck cancers at Yale that enables basic and translational science.

Extensive Research Description

American Cancer Society funded study to identify tobacco smoke mediated methylation changes in the oral mucosa as potential biomarkers of risk for head and neck squamous cell carcinoma.

Coauthors

Research Interests

Neoplasms; Otorhinolaryngologic Diseases

Selected Publications

Clinical Trials

ConditionsStudy Title
Lip, Oral Cavity and Pharynx; Other Skin; Soft TissueA Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Esophagus; Larynx; Lip, Oral Cavity and PharynxRandomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Larynx; Lip, Oral Cavity and PharynxA Phase I Study of M6620 (VX-970) in Combination With Cisplatin and XRT in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Lip, Oral Cavity and PharynxPhase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Edit Profile